Previous 10 | Next 10 |
This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...
Science stocks aren't exactly Warren Buffett's usual fare for investment. Aside from the high risks involved with trying to make new medicines and technologies, many companies that work at the cutting edge of human knowledge haven't proven their value by generating revenue. So, it shouldn't...
Scientists are still uncertain as to how quickly antibody responses against COVID-19 disappear and the level of antibody-driven protection against new coronavirus strains.However, the other component of the adaptive immunity conferred by T cells is found to remain robust against newly emergin...
Vaxart (NASDAQ: VXRT) started last month on a sour note. The phase 1 trial data for its investigational coronavirus vaccine was disappointing, and its stock sank by 58% in a single trading session. The reason: Vaxart's candidate lacked one quality considered key for a successful vac...
Vaxart 's (NASDAQ: VXRT) shares plunged 58% in one trading session after one point in a clinical trial of its coronavirus vaccine candidate disappointed investors. In this Motley Fool Live video recorded on Feb. 26, 2021 , healthcare and cannabis bureau chief Corinne Cardina and...
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwri...
In a conference call yesterday after the closing bell, Vaxart, Inc. (VXRT) CEO Andrei Floroiu addressed concerns regarding VXA-CoV2-1, its oral COVID-19 tablet vaccine candidate.In February, the company released disappointing preliminary results from its Phase 1 study of the vaccine that...
Vaxart (NASDAQ: VXRT) made some investors quite wealthy in 2020. Its shares skyrocketed more than 1,500% on increasing enthusiasm about its tablet COVID-19 vaccine program. That momentum carried over into this year, with Vaxart stock more than quadrupling year to date by early Febru...
Vaxart (VXRT): Q4 GAAP EPS of -$0.13 misses by $0.07.Revenue of $0.36M (-90.8% Y/Y) misses by $3.99M.Cash and cash equivalents of $126.9 million as of December 31, 2020Press Release For further details see: Vaxart EPS misses by $0.07, misses on revenue
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash equivalents of $126.9 million as of December 31, 2020 Conference call and webcast focused on our COVID-19 strategy scheduled for T...
News, Short Squeeze, Breakout and More Instantly...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursd...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...